Tag:

Merck

Latest Headlines

Latest Headlines

Bayer shuffles agency assignments to fold in Merck OTC brands

Bayer, which picked up Merck's consumer health unit in a $14.2 billion deal this spring, wanted to fold in all the brands from the New Jersey pharma giant's lineup. But to do so, it had to do some creative assignment shuffling. And its agencies had to take some creative steps of their own.

BBDO and JWT win, Havas loses as Bayer divvies up Merck's former OTC brands

Bayer, which picked up Merck's consumer health unit in a $14.2 billion deal this spring, wanted to fold in all the brands from the New Jersey pharma giant's lineup. But to do so, it had to do some creative assignment shuffling. And its agencies had to take some creative steps of their own.

With Opdivo approval, Bristol-Myers arms for PD-1 battle against Merck's Keytruda

Bristol-Myers scored FDA approval for its cancer immunotherapy Opdivo (nivolumab) three months ahead of schedule, setting it up for a head-to-head contest against Merck's recent debut in the same class, Keytruda.

Merck, NewLink nab $30M from BARDA to help manufacture Ebola vax

NewLink Genetics and its new partner Merck have gotten a $30 million grant from the U.S. government to help with manufacturing and development of the Ebola vaccine the two are working on.

Cubist has its Zerbaxa OK. Can Merck make the launch justify its $9.5B buyout?

Merck's $9.5 Cubist buyout got off to a rocky start when a U.S. court nixed all but one patent covering top-seller Cubicin. And now, it'll be up to brand-new FDA approval Zerbaxa to turn things around.

Cubist scores another FDA nod on the eve of its $9.5B Merck merger

Cubist Pharmaceuticals picked up FDA approval for its latest antibiotic contender, a potential blockbuster whose promise helped bring Merck to the table with a $9.5 billion buyout offer.

Lilly's Elanco disputes local paper's allegations of unsafe pet meds

A war of words has broken out over the past week between Eli Lilly's Elanco animal health division and the company's hometown newspaper, the Indianapolis Star. At issue is an overriding question that weighs on the minds of pet owners worldwide: Are medications for dogs and cats really safe?

GlaxoSmithKline's shingles shot scores in 16,000-patient study

GlaxoSmithKline rolled out data from a hefty Phase III study showing that its shingles-fighting candidate cut the risk of that disease by 97.2% in adults aged 50 and older, compared with placebo.

UPDATED: Merck beefs up its cancer drug pipeline in $375M OncoEthix buyout

Further beefing up its rapidly growing pipeline for new cancer drugs, Merck has stepped in to buy out Switzerland's OncoEthix in a deal worth upward of $375 million. And the Big Pharma player is paying a hefty premium for a BET inhibitor that was in-licensed from Mitsubishi Tanabe just two years ago.

Merck's next-gen Gardasil wins FDA approval

Merck's Gardasil follow-up is here, meaning blockbuster sales are likely on the way. But they'll come at the expense of the previous iteration.